Alterity Therapeutics (ATHE) CEO details substantial share and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Stamler David Allen
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Listed option exp 26 Feb 2027 | -- | -- | -- |
| holding | Listed option exp 31 August 2026 | -- | -- | -- |
| holding | Unlisted option exp 21 March 2029 | -- | -- | -- |
| holding | Unlisted option exp 8 August 2030 | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | American Depositary Shares (1:600 ordinary shares) | -- | -- | -- |
Holdings After Transaction:
Listed option exp 26 Feb 2027 — 1,515,152 shares (Direct);
Listed option exp 31 August 2026 — 2,380,952 shares (Direct);
Unlisted option exp 21 March 2029 — 40,000,200 shares (Direct);
Unlisted option exp 8 August 2030 — 290,400,000 shares (Direct);
Ordinary shares — 11,688,312 shares (Direct);
American Depositary Shares (1:600 ordinary shares) — 139,258 shares (Indirect, HSBC Custody Nominees (Australia) Limited)
Footnotes (1)
Key Figures
Direct ordinary shares: 11,688,312 shares
Indirect ADS holdings: 139,258 ADS
Option exp 26 Feb 2027: 1,515,152 underlying shares at $0.0280
+3 more
6 metrics
Direct ordinary shares
11,688,312 shares
Total ordinary shares directly held as of Form 3
Indirect ADS holdings
139,258 ADS
American Depositary Shares held via HSBC Custody Nominees
Option exp 26 Feb 2027
1,515,152 underlying shares at $0.0280
Listed option over ordinary shares, direct ownership
Option exp 31 Aug 2026
2,380,952 underlying shares at $0.0100
Listed option over ordinary shares, direct ownership
Option exp 21 Mar 2029
40,000,200 underlying shares at $0.0030
Unlisted option over ordinary shares, direct ownership
Option exp 8 Aug 2030
290,400,000 underlying shares at $0.0086
Unlisted option over ordinary shares, direct ownership
Key Terms
Form 3, American Depositary Shares (1:600 ordinary shares), Listed option, Unlisted option, +1 more
5 terms
Form 3 regulatory
"Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Listed option financial
"Listed option exp 26 Feb 2027 over Alterity ordinary shares"
Unlisted option financial
"Unlisted option exp 8 August 2030 with underlying ordinary shares"
indirect ownership financial
"indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees"
FAQ
What does the Alterity Therapeutics (ATHE) Form 3 filing show for CEO David Stamler?
The Form 3 shows that CEO David Stamler reported his initial beneficial ownership in Alterity Therapeutics. He holds ordinary shares directly, additional American Depositary Shares indirectly, and several option grants over ordinary shares with various exercise prices and expirations, indicating significant equity exposure.
What indirect holdings in Alterity Therapeutics does the CEO report?
The CEO reports indirect ownership of 139,258 American Depositary Shares in Alterity Therapeutics. These are held through HSBC Custody Nominees (Australia) Limited, as noted in the filing, and are reported separately from his directly held ordinary share position and option grants.
Does the Alterity Therapeutics Form 3 show any insider buying or selling activity?
The Form 3 functions as an initial ownership report and shows holdings rather than trades. The filing classifies all entries as holdings with unknown transaction codes, so it does not indicate new insider buying or selling activity, only existing positions as of the reporting date.
What are the key expiration dates for the CEO’s Alterity Therapeutics options?
The disclosed options expire on several dates: August 31, 2026; February 26, 2027; March 21, 2029; and August 8, 2030. Each expiration date corresponds to a separate option grant over a defined number of Alterity ordinary shares at a specified exercise price.